Hello, and welcome to the PaySign’s Third Quarter 2021 Earnings Conference Call and Webcast. As a remainder this conference is being recorded. This presentation may include forward-looking statements to the extent that the information presented in this presentation discusses financial projections, information or expectations about the company's business plans, results of operations, the impact of COVID-19, returns on equity, expected gross margins, markets or otherwise make statements about future events. Such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as should, may, intends, anticipates, believes, estimates, projects, forecasts, expects, plans and proposals. Although the company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions. There are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading Risk Factors and elsewhere in Form 10-K. Forward-looking statements speak only as of the date of the document in which they are contained and the company does not undertake any duty to update any forward-looking statements except as may be required by law. This presentation also includes adjusted EBITDA, a non-GAAP financial measure that is neither prepared in accordance with nor an alternative to financial measures prepared in accordance based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies. It's now my pleasure to turn the call over to CEO, Mark Newcomer. Please go ahead.

Thank you, Kevin. Good afternoon, everyone. And thank you for joining us for PaySign’s third quarter 2021 earnings call. I am Mark Newcomer, Chief Executive Officer and joining me this afternoon is Jeff Baker, our Chief Financial Officer. We are extremely pleased to report continued improvements in our revenue and operating results this quarter. Our net revenue for the quarter was 7.8 million, a $7.9 million increase from the third quarter of last year and a quarterly sequential increase of 1.1 million or 16.8%. As well as an almost three fold increase in our adjusted EBITDA as compared to second quarter of this year. Our third quarter total gross funds loaded increased 24.7% from the year ago period, and increased 7.6% from the previous quarter. Plasma gross funds loaded increased 42.7% year-over-year and 10.3% from the previous quarter. Throughout the quarter, we experienced improved results each month despite the US Customs and Border Protection decision limiting the ability for Mexican citizens to donate plasma, which remains in place. In the quarter we on boarded seven additional plasma centers bringing our total number of centers to 359. This includes the net result of the loss of four centers which were sold by a client to a non-client plasma collection company. Currently we are expecting a total of 10 Additional centers to be on boarded by the end of the year. In our patient affordability vertical we continue to see good progress and growth. During the third quarter, we launched three of the five new patient affordability programs we signed in the second quarter. We launched the fourth program in October, and the fifth program is on schedule and expected to launch in the fourth quarter. In the third quarter we renewed to form of prepaid programs and signed an additional pharma…

Thank you, Mark. Good afternoon, everyone. For all accounts, we had a solid third quarter. As mentioned in the press release, revenues, loss from operations, EBITDA and adjusted EBITDA all improved sequentially and year-over-year, and our balance sheet improves sequentially as a result of the quarter’s performance. While the third quarter continued to be impacted by COVID-19 and government stimulus measures as expected, we did see improving trends as we moved through the quarter. Of our total revenues of $7.8 million, plasma revenue accounted for $7 million, or 91%, pharma revenue was $660,000, and other revenue was $71,000. Our gross margin for the quarter was 51.1%, which was aided slightly by two pharmaceutical programs ending allowing us to recognize settlement income of under $100,000. We were able to renew both programs under our non-settlement income model. SG&A expenses were $3.6 million and total operating expenses were $4.2 million. Our net loss for the quarter was $271,000. Adjusted EBITDA, which we define as operating income plus depreciation, amortization and stock based compensation, and is a non-GAAP metric used by management to gauge the operating performance of the business was $955,000, or $0.02 per fully diluted share outstanding of 52.5 million. Third quarter gross dollar volume increased 25% versus the year ago period, as we experienced an improvement in plasma donations. Restricted cash ended the quarter at $63.3 million. Third quarter purchase volume increased 33.9% versus the year ago period and our revenue conversion rate, which is revenue divided by gross dollar loads increased over the second quarter. Taking a look at the plasma business for the quarter, revenues of $7 million were up $1.8 million from the same period last year, when the US was under a lockdown. The average revenue per month per plasma center was $6,542 versus $5,828 last…

Thanks Kevin. I'd like to again thank the PaySign team for their dedication and all their hard work during the quarter. Want to thank everybody for joining us for today's call. Thank you very much and have a nice evening.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time. And have a wonderful day. We thank you for your participation today.